Adherium Appoints Digital Health Pioneer to Lead European Business Development

/in

Digital health technology company, Adherium Limited, has appointed Scott Fleming as Senior Vice President of Business Development, Europe with immediate effect. – link here Background Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. Boasting the broadest range of “smart” medication sensors for respiratory medications globally, […]

Read more

NICE recognises Smartinhaler as best practice for asthma care

/in

Digital monitoring device proven to increase adherence and reduce hospital visits – link here The National Institute for Clinical Excellence (NICE) has recognised digital platform Smartinhaler as the most effective means of improving asthma medication adherence in new guidance. The Medtech Innovation Briefing – designed to accelerate NHS access to innovation in new treatments and […]

Read more

Adherium Expands Its International Presence, Announces Senior Appointment

/in

23 February 2017: Adherium Limited (ASX : ADR), link here a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced the appointment of a new Vice President of Business Development for its key markets outside of North America and Europe. Erin Wansbrough will lead Adherium’s partnering and market […]

Read more

AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman

/in

CATEGORY: Featured Thursday, February 23, 2017 6:50 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “In 2017, AmpliPhi plans to initiate phage therapy studies in several patient groups, which we expect will mark a key inflection point for AmpliPhi and the phage therapy field” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE […]

Read more

Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference

/in ,

DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) –Link here Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6th at 1:20PM ET. Dr. Heffernan will discuss Nexvet’s pivotal-stage clinical programs for […]

Read more

Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017

/in ,

Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017 – link here DUBLIN, Ireland, Feb. 10, 2017 (GLOBE NEWSWIRE) — Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and six month periods ended December 31, 2016. Recent highlights: Initiated pivotal field efficacy and safety studies of frunevetmab, the Company’s anti-nerve […]

Read more

‘Smart’ Inhaler System Improves Patient Outcomes in Study

/in

Posted in Mobile Health by Jamie Hartford on January 26, 2017 – link here The Smartinhaler system from New Zealand-based Adherium Ltd. connects with an app to monitor medication adherence, usage, and dosage. Daphne Allen The Smartinhaler system uses software to help providers gain insights about how patients use their medication. Smartinhaler, a “smart” personal medication monitoring system from Adherium Ltd., has shown effectiveness in reducing hospital […]

Read more

Avita Medical to Participate in the 3rd annual Biotech and Money / Medtech and Money London 2017 Conference

/in ,

Northridge, CA, Perth, Australia and London, United Kingdom – 25 January 2017 – link here. Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in new treatments for wounds and skin defects, said today that Adam Kelliher, Avita’s Chief Executive Officer, will be a panel member at the Biotech and Money / […]

Read more

AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients

/in ,

AB-SA01 meets primary endpoints of safety and tolerability and reduces S. aureus bacterial load in all patients Business update call scheduled for January 4, 2017 at 4:30 p.m. Eastern CATEGORY: Featured Monday, December 19, 2016 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB US03211P1030 “We are delighted with the […]

Read more

Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences’ Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients

/in ,

Business update call scheduled for today at 4:30 p.m. Eastern CATEGORY: Featured Wednesday, January 4, 2017 8:45 am EST – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We saw decreases in S. aureus bacterial load in all patients treated with AB-SA01 in our Phase 1 trial, which is particularly encouraging since most […]

Read more